On December 2, 2015, Ascletis Pharma Inc. closed the transaction. The company amended and received $55 million in the series A round. The company received $20 million in second tranche of series A round from a lead new investor, Goldman Sachs Group, Merchant Banking Division.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.27 HKD | 0.00% | -0.78% | -13.01% |
Apr. 03 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
Apr. 03 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.01% | 164M | |
-2.68% | 85.68B | |
+4.08% | 41.4B | |
-25.17% | 28.22B | |
+54.31% | 24.64B | |
-4.68% | 16.98B | |
-42.09% | 13.29B | |
-17.27% | 11.66B | |
-12.10% | 11.65B | |
+0.75% | 8.18B |
- Stock Market
- Equities
- 1672 Stock
- News Ascletis Pharma Inc.
- Ascletis Pharma Inc. announced that it has received $55 million in funding from Tasly Pharmaceutical Group Co., Ltd, Pavilion Capital Pte. Ltd., CBC Group, West Street Capital Partners